TRULICITY 1.5 MG OPTIONS

The demo achieved both equally its Main endpoints, with semaglutide two.4 mg demonstrating statistically considerable and remarkable advancements in liver fibrosis with no worsening of steatohepatitis, along with resolution of steatohepatitis without any worsening of liver fibrosis in those with MASH when compared to placebo.oneDistinct Populations